Jefferies Initiates Coverage On Candel Therapeutics with Buy Rating, Announces Price Target of $25
Jefferies analyst Maury Raycroft initiates coverage on Candel Therapeutics (NASDAQ:CADL) with a Buy rating and announces Price Target of $25.
Share
Why It Matters
A Wall Street analyst thinks Candel Therapeutics looks like a good buy right now. When experts start paying attention to a small company, it means they see something promising worth watching.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.